Drug Delivery Devices and Combination Products: Global Regulation & Registration

For every regulator below we answer the three questions drug delivery and combination product teams ask first: is my product a standalone device or a drug-device combination, how long will approval take, and what will it cost. Start with our pricing calculator for per-market fees and timelines.

What are drug delivery devices and combination products?

A drug delivery device is any device that administers a drug to the body: autoinjectors and prefilled syringes, insulin and other injection pens, metered-dose and dry-powder inhalers, nasal spray devices, on-body (wearable) injectors, transdermal patches, needle-free injectors, and implantable or infusion pumps. Sold empty, these are ordinary medical devices. Supplied together with the drug they deliver, they become drug-device combination products — a prefilled adrenaline autoinjector, a metered-dose inhaler, a prefilled insulin pen, or a drug-eluting stent — and the regulatory pathway changes.

The distinction that matters is not the hardware but how the drug and device are packaged and which part does the primary work. A standalone injector without a drug is a device. The same injector prefilled with a medicine is a combination product, reviewed together with that medicine. Keep the term separate from a drug delivery system in the formulation sense (nanoparticles, liposomes, polymer carriers), which is chemistry rather than a registrable device.

Every jurisdiction draws the line differently. In the United States the product's primary mode of action decides which FDA center leads the review. In the European Union an integral drug-device combination is regulated as a medicine, with a notified body opinion on the device part under MDR Article 117. Every cost below has two parts: the government fee, and our own flat annual service fee per market, from US$1,000 per year in the US (device listing and US Agent representation) and from US$2,000 per year in most other markets. Exact current figures live in our pricing calculator.

FDA drug delivery and combination product regulation (United States)

The FDA regulates drug-device combinations through the primary mode of action (PMOA). The Office of Combination Products assigns a lead center — CDRH for device-led products, CDER for drug-led, CBER for biologic-led — and 21 CFR Part 4 sets how the drug and device quality systems apply together. A delivery device sold without a drug is regulated as a device in its own right.

• Classification. A standalone delivery device (an empty pen, an infusion set, a nebulizer) is usually Class II with a 510(k). For a combination product, PMOA decides both the lead center and the submission: a device-led combination goes through CDRH as a 510(k), De Novo, or PMA; a drug-led combination rides an NDA or BLA through CDER or CBER with device constituent data. A Request for Designation (RFD) settles a contested assignment.
• Timeline. A 510(k) for a standalone device typically runs 3 to 9 months end to end; a device-led PMA or a drug-led NDA/BLA is measured in years and paced by the drug program. Early cross-center coordination and a Pre-Sub meeting save review cycles later.
• Cost. Government fees: US$26,067 for a standard 510(k) review (US$6,517 for qualified small businesses) plus US$11,423 per year in establishment registration; drug-led combinations also carry the drug program's user fees. Our flat US$1,000 per year covers FDA establishment registration and device listing maintenance plus US Agent representation; 510(k) preparation and submission are scoped as a separate project.

Autoinjectors, prefilled syringes, and on-body injectors

An autoinjector or prefilled syringe filled with its drug is a combination product, reviewed together with the medicine; the same device sold empty is a Class II device. Choosing between a prefilled syringe and an autoinjector is a human-factors and design-control decision as much as a regulatory one — both need usability engineering evidence under IEC 62366, and the device constituent of a combination product must meet 21 CFR Part 4 cGMP. On-body (wearable) injectors and needle-free injectors follow the same PMOA logic. We prepare the device constituent file — design controls, human factors, and biocompatibility — that a drug sponsor's NDA or BLA needs.

Start from our United States market page for the full FDA pathway.

EU drug-device combinations under MDR and Article 117 (European Union)

In the EU the split is sharp. An integral drug-device combination — one where the device and drug form a single product, such as a prefilled pen or a metered-dose inhaler — is regulated as a medicinal product under EU pharmaceutical law, and MDR Article 117 requires a notified body opinion on the device part before the medicine can be authorized. A device that administers a separately supplied drug, or a standalone delivery device, is regulated under MDR instead.

• Classification. Standalone delivery devices classify under the MDR rules — most active administering devices are Class IIa or IIb, and invasive or implantable delivery devices climb higher. For an integral combination, the medicine's marketing authorization governs, supported by the Article 117 notified body opinion on the device constituent.
• Timeline. Plan 9 to 18 months for a first MDR certification with a notified body, driven by notified body capacity and the maturity of your technical documentation. An Article 117 device-part opinion should be sequenced against the medicine's authorization timeline.
• Cost. There is no central government fee; the money goes to the notified body — typically €30,000 to €70,000 across a first Class IIa or IIb certification cycle, plus annual surveillance and the Article 117 opinion. Our EU Authorized Representative service is a flat annual fee from US$2,000, capped at US$4,000 as your portfolio grows, and covers EC REP representation, document review, and EUDAMED support; CE-marking work with your notified body is scoped separately.

Notified body strategy and Article 117 sequencing should shape your EU plan early; see the European Union market page for the MDR route.

Drug delivery device registration in Brazil and Latin America (ANVISA)

Brazil anchors any Latin American strategy. ANVISA classifies medical devices under RDC 751 and reviews the device on its own or, for an integral combination, alongside the medicine; Mexico's COFEPRIS is the region's second gate. Both require a local representative — we act as Brazil Registration Holder without taking control of your registration.

• Classification. RDC 751 rules follow the IMDRF model, with Classes I to IV; standalone delivery devices usually land in Class II or III. Where a product is an integral drug-device combination, the medicine pathway leads with device data supporting it.
• Timeline. Notification for a Class I-II product is typically a matter of weeks; Class III-IV registration plans for 6 to 12 months. In Mexico, COFEPRIS runs 6 to 12 months on the standard route, faster where reliance on FDA or CE approvals applies.
• Cost. ANVISA government fees: R$1,406 to notify a Class I-II product; Class III-IV family registration runs R$8,510-19,856, plus a one-time international B-GMP certification of R$72,805 where required. COFEPRIS charges MX$16,499-30,798 per product. Our registration service starts at US$2,000 per year (US$3,000 for high-risk classes) in both markets.

Start with the Brazil market page; labeling and instructions for use are prepared natively in Portuguese and Spanish.

Drug delivery device registration in Asia-Pacific: Singapore first, then ASEAN

Most overseas manufacturers enter Asia-Pacific through Singapore: HSA works in English, follows the IMDRF model, and rewards a strong FDA or CE dossier with a fast abridged review. A Singapore approval then anchors expansion across ASEAN — Malaysia, Thailand, Indonesia, Vietnam, the Philippines — where reliance-friendly frameworks make each additional market incremental. Japan and Korea are the region's big mature prizes with their own systems and languages. China is the largest market but the hardest entry — local type testing, its own combination-product rules, and the longest timelines — so treat it as its own program when the business case justifies it, not a default stop.

• Classification. Singapore's HSA uses risk classes A through D, with delivery devices typically in Class B or C, and ASEAN members track the IMDRF model under the ASEAN MDD. Japan classifies against JMDN codes; Korea's MFDS uses Classes I-IV; China's NMPA places most delivery devices in Class II or III and handles integral combinations under dedicated drug-device rules.
• Timeline. HSA abridged evaluation with a reference approval closes in 2 to 6 months; ASEAN registrations typically run 3 to 9 months per market on the same dossier. Japan plans for 9 to 14 months via PMDA; Korea 6 to 12 months including KGMP; China 12 to 24 months including type testing.
• Cost. Singapore's fees are light: an SGD 560 application plus SGD 2,010-6,250 evaluation by class, and ASEAN peers are similar (Malaysia MYR 500-3,000; Thailand THB 3,100-21,000, plus expert review THB 53,000 where required). China's NMPA fees for imported Class II-III run roughly RMB 210,000-310,000 before type testing; Japan's PMDA review fees start around ¥1 million. Our registration service starts at US$2,000 per year across Singapore and ASEAN; China, Japan, and Korea are quoted flat per market on the same model.

One well-built reference dossier does most of the region's work. See the Singapore, Malaysia, Thailand, Japan, South Korea, and China market pages.

Drug delivery device registration in Saudi Arabia and MENA (SFDA)

The Gulf is one of the fastest-growing regions in our portfolio, and its regulators are built around reliance: a strong FDA, CE, or other reference approval does most of the work when the dossier is assembled correctly. SFDA regulates medical devices and combination products and requires a local Authorized Representative; the UAE is the region's second gate.

• Classification. SFDA classifies devices into risk classes A through D on the IMDRF model, mirroring your reference-market class in most cases; the UAE's MOHAP and other MENA authorities lean on the reference approval's classification.
• Timeline. With a reference approval in hand, SFDA marketing authorization typically closes in 2 to 6 months, and UAE registration runs a similar range. Without a reference approval, expect materially longer.
• Cost. Government fees across the Gulf are modest — generally a few thousand US dollars' equivalent per authority — so the real spend is dossier assembly, Arabic labeling where required, and local representation. We quote MENA registration programs flat per market, on the same transparent model as our calculator markets.

See the Saudi Arabia and UAE market pages; we cover the wider region under one program.

Evidence, quality system, and lifecycle

Combination products carry two evidence burdens at once. The device constituent needs design controls, biocompatibility (ISO 10993), and usability engineering (IEC 62366) — human factors is decisive for injectors, pens, and inhalers that patients use unsupervised — while the drug side brings container-closure integrity, extractables and leachables, and stability data. Under 21 CFR Part 4, we reconcile the device quality system (ISO 13485 and the FDA QMSR) with drug cGMP so you run one coherent system rather than two. For the EU, we assemble the Article 117 device-part file to the notified body's expectations. Connected injectors and smart inhalers that pair with a companion app add cybersecurity documentation to the package. After launch, change assessments, complaint handling, and vigilance keep every registration current.

One program, every major market

A global drug delivery program is a sequencing problem: settle the primary mode of action, build the device constituent file once, and reuse it across FDA, EU MDR Article 117, ANVISA, and Gulf submissions. We run the full program from a single team — assignment strategy, submissions, in-country representation, and post-market maintenance — with transparent government fees and timelines in our pricing calculator.